Lilly Barba
Nephrology · Torrance, CANPI 1407835978
Payments from drug & device makers
Across 99 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$570
- Merck$324
- Veloxis Pharmaceuticals, Inc.$302
- Takeda Pharmaceuticals U.S.A., Inc.$268
- Aurinia Pharma U.S., Inc.$174
- Bayer$169
- plus $508 from 12 others
What the payments were for
- Food & beverage$2,10491%
- Education$2109%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $570 |
| Merck | 17 | $324 |
| Veloxis Pharmaceuticals, Inc. | 8 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $268 |
| Aurinia Pharma U.S., Inc. | 7 | $174 |
| Bayer | 7 | $169 |
| Vifor Pharma, Inc. | 1 | $108 |
| Abbott | 4 | $72 |
| Cook Medical LLC | 3 | $61 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| OPKO Pharmaceuticals, LLC | 2 | $44 |
| Calliditas Therapeutics US Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$108
How this compares
$2,314 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $13,928 |
| TradjentaLinagliptin | 36 | $13,649 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $11,735 |
| JanuviaSitagliptin Phosphate | 15 | $10,760 |
| EliquisApixaban | 15 | $9,947 |
| Cinacalcet Hcl | 62 | $3,763 |
| Valganciclovir Hcl | 21 | $3,084 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $2,673 |
| Ulticare Pen NeedlePen Needle, Diabetic | 24 | $1,464 |
| Nifedipine ErNifedipine | 101 | $1,385 |
| Tacrolimus | 11 | $1,086 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,015 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 20 | $977 |
| Terazosin Hcl | 84 | $800 |
| Pantoprazole Sodium | 165 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $570 | $11,73517 claims |
| MerckJanuvia | $324 | $10,76015 claims |
| PfizerEliquis | $21 | $9,94715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.
Other nephrology in Torrance
- Sharon AdlerTorrance$650K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.